Are Localized Prostate Cancer Biomarkers Useful in the Clinical Practice?

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2018 Sep 12

PMID 30204063

Citations 6

Authors

Arie Carneiro

Paulo Priante Kayano

Alan Roger Gomes Barbosa

Marcelo Langer Wroclawski

Carolina Ko Chen

Giulio Costa Cavlini

Guilherme Jose Reche

Rafael Sanchez-Salas

Marcos Tobias-Machado

Adam G Sowalsky

Bianca Bianco

Affiliations

Soon will be listed here.

Abstract

Prostate cancer presents itself in a heterogeneous way with both aggressive and indolent forms. Despite the controversy surrounding its use, prostate-specific antigen screening ultimately leads to a greater number of diagnosed patients. One of the biggest challenges in clinical practice is to select the right patients for biopsy and, among diagnosed patients, to differentiate tumors with an indolent course from those with an unfavorable prognosis, in order to determine the best therapeutic decision for each case, avoiding unnecessary interventions. Currently, several types of biomarkers are available for clinical use in patients with prostate cancer, which include blood-based (prostate-specific antigen, Prostate Health Index®, 4K score®); urine sample-based (PCA3, SelectMDx®, ExoDx Prostate IntelliScore®); and biopsy, transurethral resection, or radical prostatectomy tissue-based (ConfirmMDx®, Oncotype®, Prolaris®, Decipher®). The aim of this review is to provide an overview of the current state of evidence and to highlight recent advances in the evaluation and diagnosis of prostate cancer, with emphasis on biomarkers related to diagnosis and to prognostic evaluation of localized prostate cancer.

Citing Articles

Proteomic-based stratification of intermediate-risk prostate cancer patients.

Zhong Q, Sun R, Aref A, Noor Z, Anees A, Zhu Y Life Sci Alliance. 2023; 7(2).

PMID: 38052461 PMC: 10698198. DOI: 10.26508/lsa.202302146.

Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review.

Sequeira-Antunes B, Ferreira H Biomedicines. 2023; 11(4).

PMID: 37189669 PMC: 10135468. DOI: 10.3390/biomedicines11041051.

Integrating Serum Biomarkers into Prediction Models for Biochemical Recurrence Following Radical Prostatectomy.

Moghaddam S, Jalali A, ONeill A, Murphy L, Gorman L, Reilly A Cancers (Basel). 2021; 13(16).

PMID: 34439316 PMC: 8391749. DOI: 10.3390/cancers13164162.

Decreased levels of cathepsin Z mRNA expressed by immune blood cells: diagnostic and prognostic implications in prostate cancer.

Batista A, Franco B, Perez M, Pereira E, Rodrigues T, Wroclawski M Braz J Med Biol Res. 2021; 54(10):e11439.

PMID: 34378678 PMC: 8365873. DOI: 10.1590/1414-431X2021e11439.

Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.

Gao Y, Wang Y, Chen Y, Wang H, Young D, Shi T Cancers (Basel). 2020; 12(5).

PMID: 32429558 PMC: 7281161. DOI: 10.3390/cancers12051268.

References

Carter H, Walsh P, Landis P, Epstein J . Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002; 167(3):1231-4. View

de Kok J, Verhaegh G, Roelofs R, Hessels D, Kiemeney L, Aalders T . DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002; 62(9):2695-8. View

Raaijmakers R, Kirkels W, Roobol M, Wildhagen M, Schrder F . Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002; 60(5):826-30. DOI: 10.1016/s0090-4295(02)01958-1. View

Catalona W, Bartsch G, Rittenhouse H, Evans C, Linton H, Amirkhan A . Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol. 2003; 170(6 Pt 1):2181-5. DOI: 10.1097/01.ju.0000095460.12999.43. View

Marks L, Fradet Y, Deras I, Blase A, Mathis J, Aubin S . PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69(3):532-5. DOI: 10.1016/j.urology.2006.12.014. View

Deras I, Aubin S, Blase A, Day J, Koo S, Partin A . PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179(4):1587-92. DOI: 10.1016/j.juro.2007.11.038. View

Vickers A, Cronin A, Aus G, Pihl C, Becker C, Pettersson K . A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med. 2008; 6:19. PMC: 2474851. DOI: 10.1186/1741-7015-6-19. View

Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield X . Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009; 100(10):1603-7. PMC: 2696767. DOI: 10.1038/sj.bjc.6605058. View

Ploussard G, Haese A, van Poppel H, Marberger M, Stenzl A, Mulders P . The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. BJU Int. 2010; 106(8):1143-7. DOI: 10.1111/j.1464-410X.2010.09286.x. View

10.

Gupta A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino P . A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer. 2010; 103(5):708-14. PMC: 2938258. DOI: 10.1038/sj.bjc.6605815. View

11.

Strimbu K, Tavel J . What are biomarkers?. Curr Opin HIV AIDS. 2010; 5(6):463-6. PMC: 3078627. DOI: 10.1097/COH.0b013e32833ed177. View

12.

Auprich M, Chun F, Ward J, Pummer K, Babaian R, Augustin H . Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2010; 59(1):96-105. DOI: 10.1016/j.eururo.2010.10.024. View

13.

Cuzick J, Swanson G, Fisher G, Brothman A, Berney D, Reid J . Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12(3):245-55. PMC: 3091030. DOI: 10.1016/S1470-2045(10)70295-3. View

14.

Catalona W, Partin A, Sanda M, Wei J, Klee G, Bangma C . A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011; 185(5):1650-5. PMC: 3140702. DOI: 10.1016/j.juro.2010.12.032. View

15.

Cuzick J, Berney D, Fisher G, Mesher D, Moller H, Reid J . Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012; 106(6):1095-9. PMC: 3304411. DOI: 10.1038/bjc.2012.39. View

16.

Hansen J, Auprich M, Ahyai S, De La Taille A, van Poppel H, Marberger M . Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2012; 63(2):201-9. DOI: 10.1016/j.eururo.2012.07.030. View

17.

Stewart G, Van Neste L, Delvenne P, Delree P, Delga A, Alan McNeill S . Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2012; 189(3):1110-6. DOI: 10.1016/j.juro.2012.08.219. View

18.

McShane L, Hayes D . Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol. 2012; 30(34):4223-32. PMC: 3504327. DOI: 10.1200/JCO.2012.42.6858. View

19.

Cooperberg M, Simko J, Cowan J, Reid J, Djalilvand A, Bhatnagar S . Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013; 31(11):1428-34. DOI: 10.1200/JCO.2012.46.4396. View

20.

Bradley L, Palomaki G, Gutman S, Samson D, Aronson N . Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol. 2013; 190(2):389-98. DOI: 10.1016/j.juro.2013.02.005. View